H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL)

Wed, 03 Jun 2026 06:55:05 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $45.00 price target on Lyell Immunopharma (NASDAQ: LYEL).

The analyst commented: "Further exacerbated after Legend's (LEGN; Buy) in vivo CAR-T data, the valuation disconnect for LYEL presents a real opportunity: LYEL is down another ~13% today vs. the ~4% XBI benchmark decline, and is now down ~61% from its 52-week high of $39 per share in late December, while the XBI is up ~1% over the same period. The stock ran up after ronde-cel’s strong ASH update in 2025, then the stock faded from those 52-week highs on macro pressure,

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Mon, 01 Jun 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time.

A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Mon, 01 Jun 2026 08:00:00 -0400

A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.

Fri, 15 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26505027.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.

Fri, 15 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26505027.html

Lyell Immunopharma Announces Participation in May Investor Conferences

Tue, 12 May 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences:

H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time
2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time

Lyell Immunopharma Announces Participation in May Investor Conferences

Tue, 12 May 2026 08:00:00 -0400

H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time
2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time

Lyell Immunopharma Announces Participation in May Investor Conferences

Tue, 12 May 2026 08:00:00 -0400

H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time
2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time

Lyell Immunopharma Announces Participation in May Investor Conferences

Tue, 12 May 2026 08:00:00 -0400

H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time
2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: MWG Caph Ltd

Mon, 11 May 2026 11:12:00 -0400

si-local-file:///var/storage/secattach/20260511/26467042.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: MWG Caph Ltd

Mon, 11 May 2026 11:12:00 -0400

si-local-file:///var/storage/secattach/20260511/26467042.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Explore Investments LLC/DE

Fri, 08 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260508/26461517.html

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Explore Investments LLC/DE

Fri, 08 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260508/26461517.html

Form 10-Q Lyell Immunopharma, Inc. For: Mar 31

Wed, 06 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260506/26444091.html

Form 10-Q Lyell Immunopharma, Inc. For: Mar 31

Wed, 06 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260506/26444091.html

Form 8-K Lyell Immunopharma, Inc. For: May 06

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443851.html

Form 8-K Lyell Immunopharma, Inc. For: May 06

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443851.html

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Wed, 06 May 2026 16:05:00 -0400

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027
PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosing
Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3
Closed second $50 million tranche

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Wed, 06 May 2026 16:05:00 -0400

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027
PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosing
Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3
Closed second $50 million tranche

Baird Starts Lyell Immunopharma (LYEL) at Outperform

Fri, 01 May 2026 07:57:11 -0400

(Updated - May 1, 2026 7:57 AM EDT)

Baird analyst Jack Allen initiates coverage on Lyell Immunopharma (NASDAQ: LYEL) with a Outperform rating and a price target of $49.00.

The analyst comments "Initiating coverage with an Outperform rating and $49 price target. Lyell's pipeline is headlined by ronde-cel, an autologous CD19/CD20 CAR-T in LBCL, for which a pair of pivotal studies are ongoing. Based on the existing data we believe ronde-cel's safety/efficacy profile compares favorably to established autologous CD19 CAR-Ts (Breyanzi and Yescarta), which should allow for ronde-cel to start to gain meaningful market share (~2.5B+/year market). Beyond ronde-cel, Lyell's colorectal cancer

Baird Starts Lyell Immunopharma (LYEL) at Outperform

Fri, 01 May 2026 07:57:11 -0400

(Updated - May 1, 2026 7:57 AM EDT)

Baird analyst Jack Allen initiates coverage on Lyell Immunopharma (NASDAQ: LYEL) with a Outperform rating and a price target of $49.00.

BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously'

Fri, 01 May 2026 05:29:29 -0400

BofA Securities analyst Geoff Meacham reiterated an Underperform rating and $12.00 price target on Lyell Immunopharma (NASDAQ: LYEL)

The analyst comments "Yesterday, J&J (covered by Jason Gerberry) announced its discontinuing development of JNJ-4496, its dual CD19/CD20 CAR-T program, citing portfolio prioritization and its assessment of the treatment landscape. In our view the news is a clear setback for Lyell. Admittedly, at a surface level, we wouldn’t be surprised if Lyell bulls view the news positively with ‘4496 arguably easily one of the bigger overhangs to ronde-cel and the Lyell story. Both assets were structurally similar, with the early efficacy data directionally

Form DEFA14A Lyell Immunopharma, Inc.

Fri, 24 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260424/26365945.html

Form DEFA14A Lyell Immunopharma, Inc.

Fri, 24 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260424/26365945.html

Form ARS Lyell Immunopharma, Inc. For: Dec 31

Fri, 24 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260424/26365972.html

StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL)

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.

Lyell Immunopharma Announces Participation in May Investor Conferences

Lyell Immunopharma Announces Participation in May Investor Conferences

Lyell Immunopharma Announces Participation in May Investor Conferences

Lyell Immunopharma Announces Participation in May Investor Conferences

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: MWG Caph Ltd

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: MWG Caph Ltd

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Explore Investments LLC/DE

Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Explore Investments LLC/DE

Form 10-Q Lyell Immunopharma, Inc. For: Mar 31

Form 10-Q Lyell Immunopharma, Inc. For: Mar 31

Form 8-K Lyell Immunopharma, Inc. For: May 06

Form 8-K Lyell Immunopharma, Inc. For: May 06

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Baird Starts Lyell Immunopharma (LYEL) at Outperform

Baird Starts Lyell Immunopharma (LYEL) at Outperform

BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously'

Form DEFA14A Lyell Immunopharma, Inc.

Form DEFA14A Lyell Immunopharma, Inc.

Form ARS Lyell Immunopharma, Inc. For: Dec 31